Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-11-23 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is clearly identified as an 'RNS Number' announcement from AstraZeneca PLC, dated November 23, 2023. The content details 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), specifically reporting the purchase of ordinary shares by the Non-Executive Chair of the Board, Michel Demaré. This type of filing, reporting insider transactions (director's dealing), is explicitly covered by the definition for 'Director's Dealing' (Code: DIRS). Although it is distributed via RNS, the specific nature of the content points directly to DIRS rather than the general RNS fallback.
2023-11-23 English
TRUQAP APPROVED IN US FOR HR+ BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA approval of Truqap for HR-positive breast cancer, including clinical trial results, drug description, and regulatory status. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be reported on Forms 10-K or 10-Q. This document is not an annual report, earnings release, or management discussion, but rather a regulatory filing reporting significant corporate news and regulatory approvals. The length of the document (15,000 characters) and the detailed content confirm it is a substantive regulatory announcement rather than a brief notice or report publication announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-11-17 English
Truqap approved in US for HR+ breast cancer
Regulatory Filings Classification · 98% confidence The document is dated November 17, 2023, and is distributed via RNS (Regulatory News Service), indicated by the 'RNS Number : 8160T' header. The content announces a significant regulatory event: the US Food and Drug Administration (FDA) approval of AstraZeneca's drug Truqap in combination with Faslodex for breast cancer. This type of announcement, detailing a major regulatory milestone or corporate news released through an official channel like RNS, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV). While it is a major announcement, RNS serves as the appropriate catch-all for significant, non-standardized regulatory news releases.
2023-11-17 English
SC 13D/A
Major Shareholding Notification
2023-11-16 English
Delisting Announcement 2023
Delisting Announcement
2023-11-14 English
UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the PACIFIC-2 Phase III trial for Imfinzi, including clinical trial results and related information. The document does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is a regulatory filing providing material information about clinical trial outcomes and company developments. The document length is 12,623 characters, indicating it is a substantive report rather than a brief announcement. Given it is a Form 6-K and the content focuses on clinical trial updates rather than financial results or management changes, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-14 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.